Intraoperative infusion of esketamine

Phase 3Small molecule

NNanjing First Hospital, Nanjing Medical University

Intraoperative infusion of esketamine is one of 19 small molecule programs targeting Sleep Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sleep DisorderRecruiting

Sleep DisorderPhase 3

Recruiting

Competition

Competitive Landscape

21 competitors in Sleep Disorder

#DrugCompanyPhaseTrials

Diamox

Teva

Approved

3 2

Epidiolex

Dayvigo

Rozerem

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

2 6

Nuvigil

NNuvo Research GmbH

Approved

1 7

Kynmobi

SSamson Clinical Operations Pty Ltd

Approved

1 8

Provigil

Zocor

Rexulti

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sleep Disorder1 trial

Clinical Study of Perioperative Sleep Disorders in Cardiac Surgery

Recruiting·NNanjing First Hospital, Nanjing Medical University·Phase 4·NCT06778811·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intraoperative infusion of esketamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intraoperative infusion of esketamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intraoperative infusion of esketamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing First Hospital, Nanjing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNanjing First Hospital, Nanjing Medical University

Intraoperative infusion of esketamine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sleep Disorder1 trial

References

Drug Info

Quick Facts

Related News